Overview / Abstract: |
This Virtual Practice summarizes advances in tyrosine kinase inhibitor (TKI) treatment of chronic myeloid leukemia (CML) in the context of disease- and patient-specific characteristics; reviews the most effective methods for monitoring early response and long-term therapeutic outcomes; assesses the milestones and mutational analyses to identify when a change in TKI therapy is needed; compares toxicity profiles of the currently available TKI agents; and examines how toxicity could interact with a patient’s pre-existing comorbidities and influence adherence and outcomes. Intended Audience Educational Objectives: |
Expiration |
Oct 31, 2019 |
Discipline(s) |
Nurse Practitioner , Nursing CNE, Pharmacy CPE, Physician CME, Physician Assistant CME |
Format |
Online |
Credits / Hours |
Accreditation Statement: This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Albert Einstein College of Medicine and RedMedEd. Albert Einstein College of Medicine is accredited by the ACCME to provide continuing medical education for physicians. Credit Designation Statement: Albert Einstein College of Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity. |
Accreditation |
ACCME |
Presenters / Authors / Faculty |
Elias Jabbour, MD—Program Chair Michael W. Deininger, MD, PhD Jerald Patrick Radich, MD |
Activity Specialities / Related Topics |
Education / Teaching, Hematology, Oncology / Cancer / Radiation Therapy |
Sponsors / Supporters / Grant Providers |
Support for this activity has been provided through an educational grant from Pfizer. |
Keywords / Search Terms |
RedMedEd Einstein, RedMedEd, Free CME, CME, CE Free, chronic myeloid leukemia, CML, tyrosine kinase inhibitor, TKI, first-generation, second- and third-generation, second-generation, third-generation, side-effect, treatment advances, chronic, molecular remission/cytogenetic remission, toxicity profile, tailoring treatment, frontline Free CE CME |